- UCL and UK supermarkets unite to beat dementia
- Possible evidence for human transmission of Alzheimer’s pathology
- GABA neurotransmitter may be progressive MS marker
- Piepenbrock Group and German Center for Neurodegenerative Diseases honour Professor Hardy
- Compensation in Huntington’s disease
- Novel conceptual framework for tackling the global challenge of dementia
- BRC funding for experimental medicine research projects
- Researchers identify genetic links between epilepsy and sudden death
- Landmark 69-year study to provide window into dementia
- Study of brain changes 20 years before hereditary dementia symptoms start
- Dopamine drugs affect risk taking behaviour and happiness
- Commonly prescribed drugs affect decisions to harm oneself and others
- Research reveals how the human brain might reconstruct past events
- Research into genetic influences on epilepsy and migraines
- Fast forwarding treatment for neurodegenerative disorders at LWENC
- Natural genetic variation gives complete resistance in prion diseases
- Professor Lees awarded ABN Medal 2015
- Professor Hardy elected member of EMBO
- Working with Saracens to monitor concussion in rugby
- Mutations in two novel genes cause primary dystonia
- A new genetic switch uncovered in the long genes expressed in our brain
- Professor Alan Thompson elected to the Fellowship of the Academy of Medical Sciences
- UCL Institute of Neurology researchers awarded MRC fellowships
- Professor Ray Dolan has been elected Member of the European Academy of Sciences and Arts
- Deep brain stimulation for Tourette syndrome
- Behaviour changes common in early stage familial Alzheimer's
- Imaging shows early brain changes in FTD patients
- New test measures deadly protein in Huntington’s disease patients’ spinal fluid
- Professor Mary Reilly is elected to be the first female President of the Association of British Neurologists in 83 years
- Structure of genetic messenger molecules reveals key role in diseases
- Professor Nick Fox speaks about trial in early onset familial Alzheimer's disease at UCL
- First major exhibition to explore BSE and its impact opens at Hayward Gallery
- Government pledges £300m for dementia research
- UCL awarded £10m to develop new dementia treatments
- BRC awards £700,000 to neuroscience projects
- Acute optic neuritis: a review and proposed protocol
- Teaching Awards 2015
Parliamentary Group Visit the Institute
25 May 2012
Members of the All-party Parliamentary Group on Parkinson’s disease visited the UCL Institute of Neurology today to see at first hand the research being done at UCL to understand the causes of Parkinson’s and to develop novel treatments for the disease.
Research into Parkinson’s disease at the Institute spans fundamental research into the genetic origins of the disease, cellular studies of neuronal death and clinical interventions aiming to improve the life of people with Parkinson’s. The visit, co-organised with the charity Parkinson’s UK, brought together parliamentarians, patients and researchers.
Baroness Gale, chair of the group, said:
“this was a fascinating opportunity for members of the Parliamentary Group to see some of the research that's being done into the causes and treatments for Parkinson's. This gave me an insight into how much progress has been made, but also what still needs to be discovered”.
Professor John Hardy, Head of the Department of Molecular Neuroscience at the UCL Institute of Neurology and a leading researcher into the genetics of Parkinson’s, welcomed the visit:
“Parkinson’s disease affects 127,000 people in the UK directly as well, of course, as affecting their families and friends. It was gratifying to have the all party group come to the Institute and to see the enthusiasm and commitment of the young researchers and clinicians we have working on the disease. It is also very good for us as researchers to meet and talk to people personally affected by the disease”.
Professor Nick Wood, Galton Chair of Genetics and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, said:
“Parkinsons is a common neurodegenerative disease and there is a pressing need for research to understand the causes and develop therapies. It is therefore vital that policy makers have insights into the progress being made and the potential for therapeutic intervention to help modify and ultimately cure this devastating disease.”
The UCL Institute of Neurology is the lead partner of the UK Parkinson’s disease consortium, funded by a £5.9 million award from the Wellcome Trust and the Medical Research Council as part of their neurodegenerative diseases initiative.
UCL is Europe’s research powerhouse in neuroscience – ranked second in the world, and first in Europe, in neuroscience and behaviour by Thomson ISI Essential Science Indicators, and with more than twice as many publications and citations as any other European institution.
Neuroscience is a strategic priority for UCL, spearheaded by the new Faculty of Brain Sciences. UCL recently received a £20million grant from the Wolfson Foundation to establish The Leonard Wolfson Experimental Neurology Centre at Queen Square, which will be dedicated to the understanding and treatment of neurodegenerative diseases. This is the largest single award ever made by the Foundation and one of the largest philanthropic donations in UCL’s history. The Centre will accelerate the development of treatments and identify future therapeutic targets for neurodegenerative diseases, with the aim of earlier intervention for patients.
Baroness Gale, chair of All-Party Parliamentary Group on Parkinson's, talks to Dr Claudia Manzoni, a postdoctoral researcher in the Department of Molecular Neuroscience
Page last modified on 25 may 12 14:54